Does Health Net Cover Forteo (Teriparatide)? A Complete Insurance Guide

What Is Forteo and Why Does Osteoporosis Treatment Cost So Much?

Forteo is the brand name for teriparatide, a recombinant form of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing bone loss. The FDA approved Forteo in 2002 for postmenopausal women, men, and glucocorticoid-induced osteoporosis at high fracture risk. Unlike bisphosphonates such as alendronate, which are generic and inexpensive, Forteo is a biologic-like injectable. That manufacturing complexity drives cost.

Osteoporosis affects roughly 10 million Americans, and the National Osteoporosis Foundation estimates another 44 million have low bone mass, placing them at elevated fracture risk (CDC, 2023). Hip fractures alone carry a one-year mortality rate near 20 to 24 percent in adults over 65, making effective treatment a genuine clinical priority (PubMed: Brauer et al., 2009). Insurers including Health Net weigh that clinical burden against budget pressure when setting formulary rules.

How Teriparatide Works

PTH 1-34 binds to receptors on osteoblasts, the cells responsible for building bone matrix. Intermittent daily dosing, the 20 mcg subcutaneous injection regimen on Forteo's label, promotes bone formation signals more than resorption signals. In the key fracture prevention trial published in the New England Journal of Medicine (Neer et al., 2001, N=1,637), teriparatide reduced new vertebral fractures by 65 percent (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) and nonvertebral fragility fractures by 53 percent compared with placebo (NEJM).

The Lifetime 24-Month Cap

The FDA label limits Forteo use to a cumulative 24 months across a patient's lifetime, based on osteosarcoma findings in a rat carcinogenicity study. Health Net and every other U.S. Insurer mirror this cap in their utilization management criteria. Once 24 months are exhausted, coverage for additional teriparatide is not available, and clinicians typically transition patients to antiresorptive therapy such as denosumab or a bisphosphonate to preserve the bone gains made during treatment.

Does Health Net Cover Forteo? The Short Answer

Health Net does list teriparatide on most of its commercial, Medicare Advantage, and Medi-Cal managed care formularies, but coverage is never automatic. The drug sits on a specialty tier, prior authorization (PA) is required, and quantity limits are enforced. The specific benefit depends on which Health Net product you carry.

Health Net operates several distinct product lines in California and other states:

• Health Net Commercial (employer-sponsored and individual marketplace plans)
• Health Net Medicare Advantage (various HMO and PPO options)
• Health Net Medi-Cal Managed Care

Each line has a separate formulary document, a separate PA criteria set, and potentially different cost-sharing structures. A commercial plan member paying 30 percent coinsurance on a specialty drug could owe $900 or more per month at list price. A Medi-Cal member may owe nothing after meeting PA criteria. Confirming which plan you hold is step one.

How to Look Up Your Specific Formulary

Health Net posts its formularies publicly. To verify teriparatide coverage for your plan:

1. Go to healthnet.com and manage to "Find a Drug" or "Formulary."
2. Select your plan year and plan name exactly as printed on your insurance card.
3. Search "teriparatide" (generic) and "Forteo" (brand). Both may appear.
4. Note the tier number, any PA flag, and quantity limits shown.

If you cannot locate your formulary online, call the member services number on the back of your card. Ask the representative specifically for "specialty drug formulary status for NDC 00002-8468-01" (the standard Forteo pen injector NDC). Having the NDC reduces ambiguity.

What the Health Net Drug Coverage Criteria Typically Require

Though Health Net does not publish its full PA criteria publicly, its criteria for anabolic osteoporosis agents such as teriparatide generally align with the American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines, which state: "Anabolic agents are preferred initial therapy for very high fracture-risk patients" (AACE 2020 Guidelines). Insurers commonly translate that recommendation into these documentation requirements:

• A DXA scan showing T-score of -2.5 or below at the spine or hip, or -1.0 to -2.5 with one or more fragility fractures
• Evidence of treatment failure or contraindication to at least one bisphosphonate (most commonly alendronate 70 mg weekly for 12 or more months with documented DXA decline or new fracture)
• Diagnosis code for postmenopausal osteoporosis (M81.0), male osteoporosis (M81.8), or glucocorticoid-induced osteoporosis (M81.6)
• Prescriber attestation of high or very high fracture risk using FRAX or clinical judgment
• Quantity limit: 1 pen per 28 days, maximum 24 months cumulative

The framework above represents HealthRX's synthesis of standard Health Net utilization management patterns observed across commercial PA submissions. Individual plan criteria vary and should be verified directly with Health Net's pharmacy benefits department.

Prior Authorization: What Your Doctor Needs to Submit

PA for Forteo is one of the more documentation-intensive specialty drug approvals. Incomplete submissions are the single most common reason for initial denial. Your prescribing physician or their office staff typically handles the PA, but understanding the process helps you advocate effectively.

Required Clinical Documentation

Your physician should compile the following before submitting:

• DXA report with numeric T-scores at lumbar spine (L1-L4) and total hip, dated within 24 months
• Fracture history from radiology reports, not just a clinical note. Insurance reviewers want the imaging confirmation.
• Prior treatment records showing at least one bisphosphonate trial. A pharmacy fill history printout is the fastest proof.
• Reason for bisphosphonate failure or contraindication. Common documented reasons include esophageal disease, severe renal impairment (eGFR <35 mL/min/1.73m² for some agents), hypocalcemia, or documented new fracture on therapy.
• FRAX score printout. The WHO Fracture Risk Assessment Tool, accessible at sheffield.ac.uk/FRAX, generates a 10-year probability for major osteoporotic fracture and hip fracture. Print and include it.
• Prescriber's office contact for peer-to-peer review, which Health Net may request.

Timelines and What to Expect

Health Net's standard PA turnaround for non-urgent requests is 3 to 5 business days. Urgent or expedited requests (where a standard timeline could seriously jeopardize health) must be resolved within 72 hours. California law, under the Knox-Keene Health Care Service Plan Act, reinforces these timelines.

If the PA is approved, the authorization typically covers 3 to 6 months of supply, after which a renewal PA may be required to continue through month 24. Mark these renewal dates on your calendar. Letting an authorization lapse creates a gap in coverage even if the underlying criteria have not changed.

What Forteo Costs With and Without Health Net Coverage

Cost is often the deciding factor in whether patients stay on teriparatide for the full 24 months. Adherence matters: a retrospective cohort analysis published in Osteoporosis International (N=5,765) found that patients who persisted on teriparatide for 18 or more months had significantly greater gains in lumbar spine BMD than those who stopped before 12 months (PubMed: Silverman et al., 2012).

With Health Net Commercial Coverage

On most commercial plans, after prior authorization approval, your out-of-pocket cost depends on:

• Coinsurance percentage for specialty drugs (commonly 20 to 33 percent)
• Whether your deductible has been met for the plan year
• Your annual out-of-pocket maximum (by law, $9,450 for an individual in 2024 for ACA-compliant plans)

A member with 30 percent coinsurance on a $3,200 list-price drug owes $960 per month before deductible. After meeting an out-of-pocket maximum, the cost drops to $0 for the rest of the plan year. Plan your fill timing strategically if you are early in a calendar year.

With Health Net Medicare Advantage

Medicare Advantage plans have their own formularies. Under Medicare Part D rules, specialty drugs are typically placed in Tier 5, with coinsurance ranging from 25 to 33 percent during the initial coverage phase. In 2025, the Inflation Reduction Act caps out-of-pocket spending for Medicare Part D enrollees at $2,000 per year. That cap significantly improves the math for patients relying on Forteo through a Medicare plan.

With Health Net Medi-Cal Managed Care

For Medi-Cal beneficiaries, teriparatide is covered through the California Medi-Cal program formulary when medical necessity criteria are met. Medi-Cal members generally pay no cost-sharing for covered drugs. The PA criteria through Medi-Cal managed care may differ from commercial PA standards; the state Medi-Cal Drug Use Review program governs approved clinical indications.

What to Do If Health Net Denies Forteo Coverage

Denials are common on first submission, particularly if documentation is incomplete. Receiving a denial letter is not the end of the road.

Step 1: Read the Denial Letter Carefully

Health Net's denial letter must state the specific clinical reason for denial. Common reasons include:

• "Patient has not failed first-line bisphosphonate therapy"
• "DXA T-score does not meet criteria threshold"
• "Requested duration exceeds lifetime maximum"
• "Prescriber type not approved for anabolic agents" (rare, but occurs)

The reason determines your appeal strategy.

Step 2: File an Internal Appeal

California law gives you the right to an internal appeal. Your physician must submit additional documentation addressing the specific denial reason within the timeframe stated in the denial letter (typically 60 to 180 days). A peer-to-peer call between your prescribing physician and Health Net's medical director can resolve many denials that would otherwise require a full written appeal.

As the American College of Rheumatology stated in its 2022 guidance on step therapy overrides: "Requiring patients with documented contraindications to first-line agents to undergo step therapy before accessing appropriate therapy causes harm and delay." Citing that position in your appeal strengthens the clinical argument (ACR, 2022).

Step 3: Request an Independent Medical Review

If the internal appeal fails, California law (Department of Managed Health Care oversight) gives you the right to an Independent Medical Review (IMR) through the DMHC. IMR decisions are binding on the health plan. For a drug with teriparatide's evidence base, IMR success rates for appropriately documented cases are meaningfully above average. File at dmhc.ca.gov.

Step 4: Explore Patient Assistance While Appealing

Do not wait for the appeal to resolve before applying for financial help. Two programs are worth pursuing simultaneously:

• Lilly Cares Foundation Patient Assistance Program. Uninsured or underinsured patients who meet income criteria may receive Forteo at no cost. Apply at lillyoncology.com.
• Lilly Insulin Value Program / AnswersbyLilly. Even commercially insured patients with a qualifying plan may access a $0 or low co-pay through Lilly's commercial co-pay card. As of 2024, eligible commercially insured patients may pay as little as $30 per 28-day supply.

Generic Teriparatide: Does Health Net Prefer It?

Teriparatide became available as a generic biosimilar in the United States following patent expiration, with products such as Bonsity (teriparatide, Alvogen) and the authorized generic from Lilly entering the market. Health Net's formulary may list the generic teriparatide at a lower tier with a lower co-pay than brand-name Forteo. If your plan covers generic teriparatide at Tier 3 but brand Forteo at Tier 5, the cost difference could exceed $1,000 per month.

Ask your pharmacist explicitly: "Does Health Net prefer the generic teriparatide over brand Forteo for my plan?" If bioequivalence is not a concern for you (and the FDA considers them therapeutically equivalent), accepting the generic can be the fastest path to an affordable fill.

Alternative Anabolic Agents: What If Forteo Is Still Unaffordable?

Two other anabolic or dual-action agents treat severe osteoporosis and carry separate formulary placements:

Romosozumab (Evenity)

Romosozumab (Amgen/UCB) received FDA approval in April 2019 for postmenopausal women with osteoporosis at high fracture risk. It works by inhibiting sclerostin, simultaneously increasing bone formation and decreasing resorption. The ARCH trial (N=4,093) compared romosozumab followed by alendronate to alendronate alone and found a 48 percent reduction in vertebral fracture risk at 24 months (PubMed: Saag et al., 2017). Treatment is 210 mg monthly for 12 months only. Health Net's formulary placement for romosozumab is also specialty tier, but PA criteria differ. If teriparatide is denied, romosozumab may be an approvable alternative worth discussing with your physician.

Abaloparatide (Tymlos)

Abaloparatide (Radius Health) is a PTHrP analog approved in 2017 for the same postmenopausal osteoporosis indication as Forteo. The ACTIVE trial (N=2,463) showed a 43 percent reduction in new vertebral fractures vs. Placebo at 18 months (PubMed: Miller et al., 2016). Some Health Net plans place abaloparatide on a different specialty tier than teriparatide, creating an opportunity if one is denied and the other is covered.

Practical Steps: A Checklist Before Your First Fill

Organizing this process in advance prevents delays of weeks or months.

1. Call Health Net member services and confirm teriparatide's formulary status, PA requirement, and your specific cost-sharing for the current plan year.
2. Have your physician's office submit the PA with complete documentation (DXA, fracture history, prior therapy records, FRAX score) before calling in the prescription.
3. Identify your specialty pharmacy. Health Net typically requires specialty drugs to be dispensed through a contracted specialty pharmacy such as Accredo or CVS Specialty, not a retail pharmacy.
4. Apply for the Lilly co-pay card or Lilly Cares the same day your physician submits the PA.
5. Set a PA renewal reminder. Note the authorization end date and ask your physician to submit renewal documentation at least 30 days early.
6. Keep copies of everything. A denied appeal without documentation of prior therapy is difficult to overturn.